This Poster Presents Results from Across the AB928 Program of Four Ongoing 1b/1 Studies

AB928 PROGRAM OVERVIEW

As of data cut (07/05) of Sep 2019, a total of 10 pts have been treated with AB928 combination therapy in AB928 studies: AB928 + AB122 (n=4), AB928 + Carbo + Pem + Pembro (n=6). Overall, 10 pts have been treated with AB928 combination therapy. In AB928 combination therapy, the median (range) dose was 100 mg (50-200 mg) and the median number of dose escalations was 3 (1-7). 6 pts have been treated with AB928 in combination with chemotherapy, 1 pt with AB928 in combination with radiotherapy, and 1 pt with AB928 in combination with immunotherapy. 8 pts have been treated with AB928 in combination with other AB928 combination drugs (AB928 + AB122, AB928 + Carbo + Pem + Pembro). Overall, 10 pts have been treated with AB928 combination therapy, most due to disease progression.

AB928 IN COMBINATION EXHIBITS A FAVORABLE SAFETY PROFILE

The only DLT observed was Grade 2 rash in 1 pt (AB928 + Abi228) and the pt retired therapy and was subsequently able to complete therapy. AB928-related toxicity was evaluated in two trials. The only DLT observed was Grade 2 rash in 1 pt (AB928 + Abi228) and the pt retired therapy and was subsequently able to complete therapy. AB928-related toxicity was evaluated in two trials. AB928-related rashes are shown in Table 4. Table 4. AB928-related Grade 3 Adverse Event Profile by Treatment Group

AB928 150 MG QD SELECTED FOR RDE ACROSS BACKBONES

AB928 150 mg QD has been selected as the MTD based on PK, PD/IOC correlation, and a well tolerated safety profile of AB928 in combination with chemotherapy (PD or PD/IOC) or PD-L1 inhibition (AB928 + ICI).

PROGRAM UPDATES

- AB928-002 (TNBC and OC)
  - AB928 + PO + PR: 150 mg phase 1 dose escalation is currently ongoing. Three (17%) pts have been treated in 200 mg cohort (resulting in 3 DLTs). The majority of pts are on trial, including several pts with prolonged stable disease (SD) ≥ 4 months. All pts had previous treatments with ROS1 inhibitors and/or ICI.
- AB928-004 (CRC)
  - Greenfield's pts 4 through 9 cohorts (AB928 75 mg QD and 150 mg QD) with 9 pts on trial. The first 3 pts in each 75 mg cohort had partial response (PR), including 1 confirmed PR.
- AB928-005 (Solid Tumors)
  - Previously characterized ovarian cancer pts with disease stabilization remained on therapy with SD ≥11.6 months and the endometrial carcinoma pts with confirmed PR also continue on therapy for ≥ 6 months.

POPLAR (Ovarian Cancer)
- Cell Line Studies
- Pancreatic Cancer
- Colorectal Cancer
- Ovarian Cancer
- Solid Tumors
- Clinical Studies
- Pancreatic Cancer
- Colorectal Cancer
- Ovarian Cancer
- Solid Tumors
- Clinical Studies

AB928 IN COMBINATION EXHIBITS A FAVORABLE SAFETY PROFILE

The only DLT observed was Grade 2 rash in 1 pt (AB928 + Abi228) and the pt retired therapy and was subsequently able to complete therapy. AB928-related toxicity was evaluated in two trials. The only DLT observed was Grade 2 rash in 1 pt (AB928 + Abi228) and the pt retired therapy and was subsequently able to complete therapy. AB928-related toxicity was evaluated in two trials. AB928-related rashes are shown in Table 4. Table 4. AB928-related Grade 3 Adverse Event Profile by Treatment Group

AB928 150 MG QD SELECTED FOR RDE ACROSS BACKBONES

AB928 150 mg QD has been selected as the MTD based on PK, PD/IOC correlation, and a well tolerated safety profile of AB928 in combination with chemotherapy (PD or PD/IOC) or PD-L1 inhibition (AB928 + ICI).

PROGRAM UPDATES

- AB928-002 (TNBC and OC)
  - AB928 + PO + PR: 150 mg phase 1 dose escalation is currently ongoing. Three (17%) pts have been treated in 200 mg cohort (resulting in 3 DLTs). The majority of pts are on trial, including several pts with prolonged stable disease (SD) ≥ 4 months. All pts had previous treatments with ROS1 inhibitors and/or ICI.
- AB928-004 (CRC)
  - Greenfield’s pts 4 through 9 cohorts (AB928 75 mg QD and 150 mg QD) with 9 pts on trial. The first 3 pts in each 75 mg cohort had partial response (PR), including 1 confirmed PR.
- AB928-005 (Solid Tumors)
  - Previously characterized ovarian cancer pts with disease stabilization remained on therapy with SD ≥11.6 months and the endometrial carcinoma pts with confirmed PR also continue on therapy for ≥ 6 months.

POPLAR (Ovarian Cancer)
- Cell Line Studies
- Pancreatic Cancer
- Colorectal Cancer
- Ovarian Cancer
- Solid Tumors
- Clinical Studies
- Pancreatic Cancer
- Colorectal Cancer
- Ovarian Cancer
- Solid Tumors
- Clinical Studies

AB928 IN COMBINATION EXHIBITS A FAVORABLE SAFETY PROFILE

The only DLT observed was Grade 2 rash in 1 pt (AB928 + Abi228) and the pt retired therapy and was subsequently able to complete therapy. AB928-related toxicity was evaluated in two trials. The only DLT observed was Grade 2 rash in 1 pt (AB928 + Abi228) and the pt retired therapy and was subsequently able to complete therapy. AB928-related toxicity was evaluated in two trials. AB928-related rashes are shown in Table 4. Table 4. AB928-related Grade 3 Adverse Event Profile by Treatment Group

AB928 150 MG QD SELECTED FOR RDE ACROSS BACKBONES

AB928 150 mg QD has been selected as the MTD based on PK, PD/IOC correlation, and a well tolerated safety profile of AB928 in combination with chemotherapy (PD or PD/IOC) or PD-L1 inhibition (AB928 + ICI).

PROGRAM UPDATES

- AB928-002 (TNBC and OC)
  - AB928 + PO + PR: 150 mg phase 1 dose escalation is currently ongoing. Three (17%) pts have been treated in 200 mg cohort (resulting in 3 DLTs). The majority of pts are on trial, including several pts with prolonged stable disease (SD) ≥ 4 months. All pts had previous treatments with ROS1 inhibitors and/or ICI.
- AB928-004 (CRC)
  - Greenfield’s pts 4 through 9 cohorts (AB928 75 mg QD and 150 mg QD) with 9 pts on trial. The first 3 pts in each 75 mg cohort had partial response (PR), including 1 confirmed PR.
- AB928-005 (Solid Tumors)
  - Previously characterized ovarian cancer pts with disease stabilization remained on therapy with SD ≥11.6 months and the endometrial carcinoma pts with confirmed PR also continue on therapy for ≥ 6 months.

POPLAR (Ovarian Cancer)
- Cell Line Studies
- Pancreatic Cancer
- Colorectal Cancer
- Ovarian Cancer
- Solid Tumors
- Clinical Studies
- Pancreatic Cancer
- Colorectal Cancer
- Ovarian Cancer
- Solid Tumors
- Clinical Studies

AB928 IN COMBINATION EXHIBITS A FAVORABLE SAFETY PROFILE

The only DLT observed was Grade 2 rash in 1 pt (AB928 + Abi228) and the pt retired therapy and was subsequently able to complete therapy. AB928-related toxicity was evaluated in two trials. The only DLT observed was Grade 2 rash in 1 pt (AB928 + Abi228) and the pt retired therapy and was subsequently able to complete therapy. AB928-related toxicity was evaluated in two trials. AB928-related rashes are shown in Table 4. Table 4. AB928-related Grade 3 Adverse Event Profile by Treatment Group

AB928 150 MG QD SELECTED FOR RDE ACROSS BACKBONES

AB928 150 mg QD has been selected as the MTD based on PK, PD/IOC correlation, and a well tolerated safety profile of AB928 in combination with chemotherapy (PD or PD/IOC) or PD-L1 inhibition (AB928 + ICI).

PROGRAM UPDATES

- AB928-002 (TNBC and OC)
  - AB928 + PO + PR: 150 mg phase 1 dose escalation is currently ongoing. Three (17%) pts have been treated in 200 mg cohort (resulting in 3 DLTs). The majority of pts are on trial, including several pts with prolonged stable disease (SD) ≥ 4 months. All pts had previous treatments with ROS1 inhibitors and/or ICI.
- AB928-004 (CRC)
  - Greenfield’s pts 4 through 9 cohorts (AB928 75 mg QD and 150 mg QD) with 9 pts on trial. The first 3 pts in each 75 mg cohort had partial response (PR), including 1 confirmed PR.
- AB928-005 (Solid Tumors)
  - Previously characterized ovarian cancer pts with disease stabilization remained on therapy with SD ≥11.6 months and the endometrial carcinoma pts with confirmed PR also continue on therapy for ≥ 6 months.